2012 Scrip 100: Regeneron eyes a bright future
This article was originally published in Scrip
Executive Summary
Regeneron has shown how a company can leverage itself successfully through R&D partnerships, and become one of the top 10 biotech companies in terms of R&D spend. CEO Dr Len Schleifer talks to Nancy Faigen about the company's profitable partnerships and a rich deal with Sanofi.